Agile Therapeutics (NASDAQ:AGRX) Shares Pass Below 200-Day Moving Average of $1.21

Agile Therapeutics, Inc. (NASDAQ:AGRXGet Free Report) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.21 and traded as low as $0.36. Agile Therapeutics shares last traded at $0.39, with a volume of 39,728 shares traded.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on AGRX shares. Maxim Group reiterated a “hold” rating on shares of Agile Therapeutics in a research note on Monday, March 18th. initiated coverage on Agile Therapeutics in a research report on Wednesday. They issued a “sell” rating for the company.

Check Out Our Latest Stock Analysis on Agile Therapeutics

Agile Therapeutics Trading Up 5.1 %

The company has a market capitalization of $2.70 million, a PE ratio of -0.11 and a beta of 1.25. The business’s fifty day moving average is $0.41 and its two-hundred day moving average is $1.21.

Agile Therapeutics (NASDAQ:AGRXGet Free Report) last posted its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) earnings per share for the quarter. The firm had revenue of $5.72 million during the quarter.

Institutional Trading of Agile Therapeutics

An institutional investor recently raised its position in Agile Therapeutics stock. Armistice Capital LLC grew its position in shares of Agile Therapeutics, Inc. (NASDAQ:AGRXFree Report) by 10.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 108,000 shares of the specialty pharmaceutical company’s stock after buying an additional 10,000 shares during the quarter. Armistice Capital LLC owned 3.65% of Agile Therapeutics worth $211,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 10.92% of the stock is currently owned by institutional investors.

About Agile Therapeutics

(Get Free Report)

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Further Reading

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with's FREE daily email newsletter.